Yamanouchi Pharmaceutical Company Ltd.

Astellas Pharma Gmbh

Yoshinori Okamoto

Makoto Takeuchi

Yasuhiro Yonetoku

Hirokazu Kubota

Yasuo Isomura

Souichirou Kawazoe

Akira Toyoshima

Ryo Naito

Masashi Funatsu

Jun Ishikawa

Masahiko Hayakawa

Keizo Sugasawa

Ken Ikeda

Masayuki Saito

Noriyuki Kawano

Ippei Sato

Issei Tsukamoto

Hisao Hamaguchi

Yuji Matsushima

Masato Satoh

Masahiro Iwata

Takeshi Hondo

Kazuo Honda

Akito Nishida

Kazuhisa Takayama

Fusako Nishigaki

Motonori Aoki

Akira Niwa

Susumu Igarashi

Hiroyuki Kanoh

Masato Kobori

Keizou Sugasawa

Yutaka Kondoh

A novel and excellent method for preventing and/or treating diseases related to a cannabinoid type 2 receptor, based on an agonistic action on a cannabinoid type 2 receptor. It was found that a hetero ring derivative mainly having two substituents, for example, a pyrimidine-5-carboxamide derivative having a substituent amino group at the 2-position, exhibits a potent agonistic action on a cannabinoid type 2 receptor, and can be an agent for preventing and/or treating diseases related to a cannabinoid type 2 receptor such as inflammatory diseases, pain, and the like.

Pyrimidine compound

Drugs, in particular, pyrazole derivatives represented by the following general formula (I) which have a calcium release-activated calcium channel inhibitory effect and medicinal compositions, in particular, calcium release-activated calcium channel inhibitors containing the above compounds as the active ingredient, (in the formula, each symbol has the following meaning:D: pyrazolyl which may have 1 to 3 substituents selected from the group consisting of -Alk, -lower alkenyl, -lower alkynyl, -halogeno-lower alkyl, -Alk-cycloalkyl, -Alk-O-Alk, -cycloalkyl, &#x2014;O-Alk, &#x2014;COOH, &#x2014;COO-Alk and -Hal,n: 0 or 1,B: phenylene, a nitrogen-containing, divalent, saturated ring group, or a monocyclic, divalent heteroaromatic ring group which may be substituted with Alk,X: &#x2014;NR&#x2014;CRR&#x2014;, &#x2014;CRR&#x2014;NR&#x2014;, &#x2014;NR&#x2014;SO&#x2014;, &#x2014;SO&#x2014;NR&#x2014; or &#x2014;CR&#x2550;CR&#x2014;, andA: benzene ring which may have one or more substituents; mono-, di- or tricyclic fused heteroaryl which may have one or more substituents; cycloalkyl which may have one or more substituents; a nitrogen-containing, saturated ring group which may have one or more substituents; lower alkenyl which may have one or more substituents; lower alkynyl which may have one or more substituents; or Alk which may have one or more substituents).

Pyrazole derivative

Drugs, in particular, pyrazole derivatives represented by the following general formula (I) which have a calcium release-dependent calcium channel inhibitory effect and medicinal compositions, in particular, calcium release-dependent calcium channel inhibitors containing the above compounds as the active ingredient, (in the formula, each symbol has the following meaning:

As a result of an effort made by us for the purpose of developing a therapeutic agent having a bone formation-stimulating effect by promoting the functions of osteoblasts, the present inventors discovered that a certain nitrogen-containing heterocyclic compound exhibits a potent bone formation-stimulating effect on the osteoblast and thus can serve as an excellent prophylactic or therapeutic agent against a metabolic bone disease, whereby establishing the present invention. Thus, the present invention provides a 3,6-disubstituted 1,2,4-triazolo[4,3-b]pyridazine compound or a pharmaceutically acceptable salt thereof as well as a pharmaceutical composition comprising such a compound and a pharmaceutically acceptable carrier, especially a bone-forming agent.

Nitrogen-containing heterocyclic compound

Pharmaceutical compound comprising a pyrazole derivative and methods of using the same for the treatment of calcium release-activated calcium channel associated diseases

Quinuclidine derivatives represented by general following general formula (I), salts, N-oxides or quaternary ammonium salts thereof, and medicinal compositions containing the same.

Quinuclidine derivatives and medicinal composition thereof

Naphthyridine derivatives and pharmaceutical compositions thereof

This invention relates to novel benzodiazepine derivatives represented by the following general formula (I) or pharmaceutically acceptable salts thereof, ##STR1## (wherein R.sup.1 is an aryl group, or an aromatic heterocyclic radical of 5-membered monocyclic, 6-membered monocyclic or 5- and 6-membered bicyclic structure, which may optionally be substituted; and R.sup.2 is an aryl group which may optionally be substituted), to medicinal compositions comprising the same, and to a process for producing the same. The compounds of formula (I) shown above exhibit antagonism for the CCK-B receptor and the action of depressing the gastric acid secretion caused by the stimulus of pentagastrin, and are therefore useful as a drug for the relief of diseases related to the CCK-B receptor and the gastrin receptor.

Benzodiazepine aryl urea derivatives

Growing community of inventors

Ibaraki, Japan

Yoshinori Okamoto